Keratoconus - Pipeline Insight, 2025
Description
DelveInsight’s, “Keratoconus - Pipeline Insight, 2025” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Keratoconus pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Keratoconus: Overview
Keratoconus is an eye (ocular) disorder characterized by progressive thinning and changes in the shape of the cornea. The cornea is the thin, clear outer layer of the eye and is normally dome-shaped. Slowly progressive thinning of the cornea causes a cone-shaped bulge to develop towards the center of the cornea in the areas of greatest thinning. Affected individuals develop blurry or distorted vision, sensitivity to light (photophobia), and additional vision problems. Keratoconus often begins at puberty and most often is seen in teenagers or young adults. The specific underlying cause is not fully understood and most likely the condition results from the interaction of multiple factors including genetic and environmental ones.
The corneas in both eyes are usually affected (bilateral), although the progression and severity of the condition in each eye may differ (asymmetric development), which means one eye may be notably worse than the other. Symptoms usually become apparent during adolescence or young adulthood (i.e. late teens through early 20s). Keratoconus may become progressively worse for 10 to 20 years before slowing. Older adults typically do not have worsening of keratoconus. Because of the progressive nature of the disorder, affected individuals may have to change glasses frequently.
Keratoconus may be diagnosed based upon a complete patient and family history and thorough eye examination. Such an examination may include evaluation of the external appearance of the eyes, visual acuity, eye movements, and visual fields; the use of a special, illuminated microscope that allows physicians to view the eye through high magnification (slit-lamp examination); and/or additional tests or procedures.
The treatment of keratoconus is based upon the severity of the condition in the individual and the rate of progression of the disorder. In some individuals with mild symptoms, vision may be improved with the use of appropriate eyeglasses or soft contact lenses. However, progressive changes in vision often necessitate frequent prescription changes.
""Keratoconus- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Keratoconus pipeline landscape is provided which includes the disease overview and Keratoconus treatment guidelines. The assessment part of the report embraces, in depth Keratoconus commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Keratoconus collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Keratoconus report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Keratoconus Emerging Drugs
Further product details are provided in the report……..
Keratoconus: Therapeutic Assessment
This segment of the report provides insights about the different Keratoconus drugs segregated based on following parameters that define the scope of the report, such as:
Keratoconus: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Keratoconus therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Keratoconus drugs.
Keratoconus Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Keratoconus: Overview
Keratoconus is an eye (ocular) disorder characterized by progressive thinning and changes in the shape of the cornea. The cornea is the thin, clear outer layer of the eye and is normally dome-shaped. Slowly progressive thinning of the cornea causes a cone-shaped bulge to develop towards the center of the cornea in the areas of greatest thinning. Affected individuals develop blurry or distorted vision, sensitivity to light (photophobia), and additional vision problems. Keratoconus often begins at puberty and most often is seen in teenagers or young adults. The specific underlying cause is not fully understood and most likely the condition results from the interaction of multiple factors including genetic and environmental ones.
The corneas in both eyes are usually affected (bilateral), although the progression and severity of the condition in each eye may differ (asymmetric development), which means one eye may be notably worse than the other. Symptoms usually become apparent during adolescence or young adulthood (i.e. late teens through early 20s). Keratoconus may become progressively worse for 10 to 20 years before slowing. Older adults typically do not have worsening of keratoconus. Because of the progressive nature of the disorder, affected individuals may have to change glasses frequently.
Keratoconus may be diagnosed based upon a complete patient and family history and thorough eye examination. Such an examination may include evaluation of the external appearance of the eyes, visual acuity, eye movements, and visual fields; the use of a special, illuminated microscope that allows physicians to view the eye through high magnification (slit-lamp examination); and/or additional tests or procedures.
The treatment of keratoconus is based upon the severity of the condition in the individual and the rate of progression of the disorder. In some individuals with mild symptoms, vision may be improved with the use of appropriate eyeglasses or soft contact lenses. However, progressive changes in vision often necessitate frequent prescription changes.
""Keratoconus- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Keratoconus pipeline landscape is provided which includes the disease overview and Keratoconus treatment guidelines. The assessment part of the report embraces, in depth Keratoconus commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Keratoconus collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Keratoconus R&D. The therapies under development are focused on novel approaches to treat/improve Keratoconus.
This segment of the Keratoconus report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Keratoconus Emerging Drugs
- EpiSmart: Epion Therapeutics, Inc.
- IVMED-80: iVeena Delivery Systems
Further product details are provided in the report……..
Keratoconus: Therapeutic Assessment
This segment of the report provides insights about the different Keratoconus drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Keratoconus
- There are approx. 3+ key companies which are developing the therapies for Keratoconus. The companies which have their Keratoconus drug candidates in the most advanced stage, i.e. phase III include, Epion Therapeutics, Inc.
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
- Product Type
Keratoconus: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Keratoconus therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Keratoconus drugs.
Keratoconus Report Insights
- Keratoconus Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Keratoconus drugs?
- How many Keratoconus drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Keratoconus?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Keratoconus therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Keratoconus and their status?
- What are the key designations that have been granted to the emerging drugs?
- Epion Therapeutics, Inc.
- iVeena Delivery Systems
- EpiSmart
- IVMED-80
Table of Contents
60 Pages
- Introduction
- Executive Summary
- Keratoconus: Overview
- Causes
- Pathophysiology
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Keratoconus– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- EpiSmart: Epion Therapeutics, Inc.
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- IVMED-80: iVeena Delivery Systems
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- Comparative Analysis
- Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Keratoconus Key Companies
- Keratoconus Key Products
- Keratoconus- Unmet Needs
- Keratoconus- Market Drivers and Barriers
- Keratoconus- Future Perspectives and Conclusion
- Keratoconus Analyst Views
- Keratoconus Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
